Managing Adverse Events Associated With Immunotherapy in Bladder Cancer

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, shares his recommendation for how to manage the side effects of immunotherapy as a monotherapy, particularly PD-1/PD-L1 agents, in patients with bladder cancer.

Bellmunt emphasizes that the side effects do not always appear right away in this patient population. If a side effect is not recognized early enough, it can become life threatening for a patient.